Coherus BioSciences, Inc. - stock earnings
CHRS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -79.7 million USD | 91.5 million USD |
| 2023Q3 | -39.6 million USD | 74.6 million USD |
| 2023Q2 | -42.9 million USD | 58.7 million USD |
| 2023Q1 | -74.8 million USD | 32.4 million USD |
| 2022Q4 | -66.2 million USD | 45.4 million USD |
| 2022Q3 | -92.9 million USD | 45.4 million USD |
| 2022Q2 | -56.3 million USD | 60.2 million USD |
| 2022Q1 | -111.2 million USD | 60.1 million USD |
| 2021Q4 | -45.7 million USD | 73.4 million USD |
| 2021Q3 | -38.5 million USD | 82.5 million USD |
| 2021Q2 | -29.9 million USD | 87.6 million USD |
| 2021Q1 | -172.9 million USD | 83.0 million USD |
| 2020Q4 | 9.7 million USD | 110.4 million USD |
| 2020Q3 | 27.9 million USD | 113.6 million USD |
| 2020Q2 | 59.0 million USD | 135.7 million USD |
| 2020Q1 | 35.6 million USD | 116.2 million USD |
| 2019Q4 | 39.2 million USD | 123.9 million USD |
| 2019Q3 | 47.0 million USD | 111.7 million USD |
| 2019Q2 | 23.6 million USD | 83.4 million USD |
| 2019Q1 | -20.0 million USD | 37.1 million USD |
| 2018Q4 | -62.6 million USD | ? USD |
| 2018Q3 | -58.8 million USD | ? USD |
| 2018Q2 | -43.6 million USD | ? USD |
| 2018Q1 | -44.3 million USD | ? USD |
| 2017Q4 | -49.1 million USD | 1.6 million USD |
| 2017Q3 | -59.0 million USD | 1.4 million USD |
| 2017Q2 | -55.3 million USD | 1.4 million USD |
| 2017Q1 | -74.8 million USD | 161000 USD |
| 2016Q4 | -75.9 million USD | 844000 USD |
| 2016Q3 | 83.9 million USD | 162.8 million USD |
| 2016Q2 | -70.0 million USD | 14.1 million USD |
| 2016Q1 | -65.4 million USD | 12.4 million USD |
| 2015Q4 | -52.4 million USD | 10.2 million USD |
| 2015Q3 | -71.3 million USD | 7.2 million USD |
| 2015Q2 | -58.8 million USD | 6.9 million USD |
| 2015Q1 | -40.7 million USD | 5.8 million USD |
| 2014Q4 | -29.1 million USD | 6.5 million USD |
| 2014Q3 | -7.9 million USD | 16.1 million USD |
| 2014Q2 | -25.0 million USD | 5.0 million USD |
| 2014Q1 | -25.2 million USD | 3.6 million USD |
| 2013Q4 | -14.6 million USD | 1.2 million USD |
| 2013Q3 | -21.5 million USD | 506000 USD |
| 2013Q2 | ? USD | 1.0 million USD |
| 2012Q4 | ? USD | 1.9 million USD |
CHRS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -237.9 million USD | 257.2 million USD |
| 2022 | -326.6 million USD | 211.0 million USD |
| 2021 | -306.3 million USD | 326.6 million USD |
| 2020 | 132.2 million USD | 475.8 million USD |
| 2019 | 89.8 million USD | 356.1 million USD |
| 2018 | -209.3 million USD | 1.6 million USD |
| 2017 | -238.2 million USD | 1.6 million USD |
| 2016 | -127.3 million USD | 190.1 million USD |
| 2015 | -223.3 million USD | 30.0 million USD |
| 2014 | -87.1 million USD | 31.1 million USD |
| 2013 | -53.6 million USD | 2.8 million USD |
| 2012 | -33.0 million USD | 1.9 million USD |
CHRS
Price: $2.04
52 week price:
Earnings Per Share: -2.53 USD
P/E Ratio: -1.03
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 749400
Ebitda: -55.8 millionMarket Capitalization: 251.4 million